CAR-T Immuno-Oncology

Home / Products / CAR-T Immuno-Oncology

Indication: Various Cancers

Technology Platform: Chimeric Antigen Receptor T cell (CAR-T) therapy CAR-T cell therapy involves engineering cancer patients’ own immune cells to recognize and attack their tumors.

The Company has acquired Chinese PLA General Hospital’s (“PLAGH”, Beijing, also known as “301 Hospital”) Chimeric Antigen Receptor T cell (CAR-T) therapy, its recombinant expression vector CD19, CD20, CD30 and Human Epidermal Growth Factor Receptor’s (EGFR or HER1) Immuno-Oncology patents (all pending), and Phase I/II clinical data of the aforementioned therapies and manufacturing knowledge. VIEW PRESS RELEASE HERE

CAR-T TherapyIndication
CD19Acute B lymphocytic leukemia
CD20Progressive malignant lymphoma
CD30Hodgkin’s lymphoma
EGFR (HER1)Advanced lung cancer